Fred Bernard Craves

Synta Pharmaceuticals Corp. discovers, develops and commercializes pharmaceutical products. It focuses on the research, development and commercialization of oncology medicines that provides treatment to cancer patients. The company is also developing a proprietary platform for delivery of anti-cancer drugs directly to tumor cells, known as Hsp90-inhibitor drug conjugates. Synta Pharmaceuticals was founded by Safi R. Bahcall and Lan-Bo Chen in March 2000 and is headquartered in Lexington, MA.

Codon Devices, Inc. produces pharmaceuticals and biorefineries for the production of industrial chemicals and bio-energy. The firm designs and constructs biological components such as enzymes, biopharmaceuticals, and cell lines for improved function. Its customers include the biotechnology, pharmaceutical, and agriculture sectors. The company was founded by Noubar B. Afeyan, George Church, Drew Endy, Joseph M. Jacobson and Jay Keasling in 2004 and is headquartered in Cambridge, MA.

Ion Torrent Systems, Inc. develops semiconductor chips for DNA sequencing systems. The company was founded in 2007 and is headquartered in Guilford, CT.

Galileo Pharmaceuticals, Inc. develops therapeutics and pharmaceuticals for redox failure such as stroke, heart attack, and diabetes. It also owns and operates laboratories. The company was founded by Dr. Guy Miller in 1998 and is headquartered in Santa Clara, CA.

Incyte Pharmaceuticals, Inc. engages in the provision of biopharmaceutical services. The company was founded in April, 1991 is headquartered in Palo Alto, CA.

EOS Biotechnology, Inc. develops therapeutic and diagnostic drugs. The company was founded by Herbert L. Heyneker, John Lowe, David H. Mack, David W. Martin, Richard Murray, and Stephen W. Weiss and is headquartered in Fermont, California.

Bay City Capital LLC (Bay City Capital) is a venture capital firm founded in 1997 by Fred Craves, John Diekman, and Thomas Pritzker. The firm is headquartered in San Rafael, California.

BioSeek, an Asterand company, is improving the success rate of pharmaceutical research and development by integrating human biology from the earliest stages of drug discovery onward. Their BioMAP® Systems incorporate predictive primary human cell-based disease models that generate uniquely informative biological activity profiles for each potential drug. As a result, their technology drives the selection and development of new drug candidates. they leverage their BioMAP® Systems technology in collaborations to enhance the productivity of their pharmaceutical partners' pipelines to identify promising compounds for therapeutic development. Asterand plc acquired BioSeek on February 18, 2010. Asterand is the leading global supplier of high quality, well characterized human tissue and human tissue-based research services to drug discovery scientists. BioSeek's BioMAP® platform and primary human cell based assays are highly complementary to the human tissue-based products and services offered by Asterand. Formed in January 2006 from the merger of Asterand, a human tissue biorepository, and Pharmagene, a human tissue-based drug discovery company, Asterand plc is uniquely positioned to provide a comprehensive approach to meet the research needs of pharmaceutical and biotechnology companies. From their offices in Royston (United Kingdom), San Francisco, California and Detroit, Michigan they have more than 90 employees focused on providing services and products to accelerate drug discovery research from target identification through to compound evaluation and drug safety.

GENTURAdx USA, Inc. manufactured biotechnology instruments. The firm provided tools necessary for detection and treatment of diseases and drug discoveries. It had offices in the Silicon Valley, Hong Kong, Shanghai and Suzhou. The company was founded by Steve Yu and Jesus Ching in June 2005 and was headquartered in Hayward, CA.

Synchronicity Pharma, Inc. discovers, develops and commercializes novel therapeutics. Its products identify components of the circadian system that can be targeted to treat metabolic and related disorders, such as diabetes, obesity, and cardiovascular diseases. The company was founded by Ross S. Bersot, Joseph S. Takahashi, Masashi Yanagisawas and Ron Evans in 2008 and is headquartered in San Jose, CA.

Dermira, Inc. is a biopharmaceutical company. It engages in the provision of therapies for chronic skin conditions. The company was founded by Thomas G. Wiggans, Eugene Andrew Bauer, Luis C. Peña, and Christopher M. Griffith on August 18, 2010 and is headquartered in Indianapolis, IN.

Madrigal Pharmaceuticals, Inc. develops small-molecule drugs addressing major unmet needs in cardiovascular and metabolic diseases. It specializes in the treatment of both niche and prevalent indications, including fatty liver disease and non-alcoholic steatohepatitis, diabetes, dyslipidemia, and cardiovascular disease. The company was founded by Rebecca A. Taub, Brian N. Cunningham, and Edward Chiang in September 2011 and is headquartered in Fort Washington, PA.

IIF Management Co LLC (Illumina Ventures) is a venture capital firm founded in 2015 by Nicholas J. Naclerio. The firm is headquartered in Foster City, California.

Bay City Capital GF Xinde International Life Sciences USD Fund LP invests in companies located United States, Canada, Western Europe and China. The Fund targets companies operating in the fields of life sciences. It provides financing for seed, early and later stage capital requirements.

KBP Biosciences engages in conducting biotechnological research to develop therapies for patients. The company was founded by Huang Zhenhua in and is headquartered in Princeton, NJ.

Imidomics, Inc. is an American biotechnology company that focuses on discovering and developing new medicines for immune-mediated inflammatory diseases (IMIDs). The company is based in an undisclosed location. Imidomics has access to the IMID-biobank, which includes real-world data from clinical records and biological samples from over 17,000 IMID patients and control subjects across six indications. The company utilizes a proprietary digital bioinformatics portal called the Imidomics Precision Discovery Platform to generate novel insights into disease mechanisms and identify potential new drug targets. The company was founded in Barcelona in 2015 by Dr. Sara Marsal and Dr. Richard M. Myers. The CEO of the company is Fred Bernard Craves.